{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:46:35Z","timestamp":1791193595452,"version":"4.1.0"},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T00:00:00Z","timestamp":1067385600000},"content-version":"vor","delay-in-days":2492,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:p> <jats:bold>OBJECTIVE\u2003At present, there are no reports in the literature of studies in humans concerning a possible role of nitric oxide (NO) in the regulation of pancreatic endocrine secretions, whereas studies in the rat provided discrepant results. The aim of this study was to clarify whether NO is involved in the control of insulin and\/or glucagon secretion in basal conditions and\/or in response to arginine or glucose administration in normal male subjects.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>DESIGN\u2003We investigated whether an intravenous infusion of the NO synthase (NOS) inhibitor L\u2010NAME, at a dose previously demonstrated not to produce blood pressure alterations or untoward side\u2010effects, modifies insulin and\/or glucagon secretory patterns.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>SUBJECTS\u2003Fourteen healthy male volunteers aged 24\u201335 years, within 10\u201313% of their ideal body weight and without family history of diabetes mellitus or other endocrine diseases.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>METHODS\u2003Seven normal men were treated intravenously with <jats:sc>L<\/jats:sc>\u2010arginine (30g in 50ml of normal saline over 30 minutes) or glucose (0.33g\/kg body weight in a bolus) with or without the concomitant infusion of L\u2010NAME (90\u03bcg\/kg in 50\u2003ml of normal saline). L\u2010NAME was infused for 30 minutes before and during arginine infusion and over 30 minutes before and 30 minutes after glucose injection. Another group of 7 men was infused over 60 minutes with L\u2010NAME (90\u03bcg\/kg in 50\u2003ml of normal saline) alone or saline alone.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>RESULTS\u2003Basal and <jats:sc>L<\/jats:sc>\u2010arginine or glucose induced glucagon secretions and basal and glucose stimulated insulin secretions were not altered by L\u2010NAME administration. In contrast, the drug produced a partial but significant decrease in the insulin response to <jats:sc>L<\/jats:sc>\u2010arginine. In fact, the mean peak insulin response to <jats:sc>L<\/jats:sc>\u2010arginine was 5.3 times (53\u00b15mU\/l (mean\u00b1SE)) higher than basal value (10\u00b12) in the absence of L\u2010NAME, but only 3.33 times (40\u00b14) higher than baseline (12\u00b13) during the infusion of the NOS\u2010inhibitor.<\/jats:bold> <\/jats:p><jats:p> <jats:bold>CONCLUSION\u2003These data suggest that NO at least partially mediates the stimulatory action of <jats:sc>L<\/jats:sc>\u2010arginine on insulin secretion in normal human subjects.<\/jats:bold> <\/jats:p>","DOI":"10.1046\/j.1365-2265.1997.d01-1745.x","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T20:06:43Z","timestamp":1068235603000},"page":"115-119","source":"Crossref","is-referenced-by-count":13,"title":["<b>Involvement of nitric oxide in arginine, but not glucose, induced insulin secretion in normal men<\/b>"],"prefix":"10.1111","volume":"46","author":[{"given":"V.","family":"Coiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Capretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Speroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Caffarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chiodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,10,29]]},"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.d01-1745.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.1997.d01-1745.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.1997.d01-1745.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T09:18:15Z","timestamp":1698484695000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.1997.d01-1745.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["10.1046\/j.1365-2265.1997.d01-1745.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.1997.d01-1745.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]}}}